Compare Lupin with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN AUROBINDO PHARMA LUPIN/
AUROBINDO PHARMA
 
P/E (TTM) x 26.1 8.2 319.9% View Chart
P/BV x 3.2 2.0 159.7% View Chart
Dividend Yield % 0.7 0.5 126.9%  

Financials

 LUPIN   AUROBINDO PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-21
AUROBINDO PHARMA
Mar-21
LUPIN/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1221,023 109.7%   
Low Rs576333 172.7%   
Sales per share (Unadj.) Rs334.2422.8 79.0%  
Earnings per share (Unadj.) Rs27.092.0 29.4%  
Cash flow per share (Unadj.) Rs46.6110.0 42.4%  
Dividends per share (Unadj.) Rs6.504.00 162.5%  
Avg Dividend yield %0.80.6 129.8%  
Book value per share (Unadj.) Rs300.1374.3 80.2%  
Shares outstanding (eoy) m453.68585.94 77.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x2.51.6 158.3%   
Avg P/E ratio x31.47.4 425.7%  
P/CF ratio (eoy) x18.26.2 295.4%  
Price / Book Value ratio x2.81.8 156.1%  
Dividend payout %24.04.3 552.8%   
Avg Mkt Cap Rs m385,072397,398 96.9%   
No. of employees `000NANA-   
Total wages/salary Rs m28,25935,350 79.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m151,630247,746 61.2%  
Other income Rs m1,3633,809 35.8%   
Total revenues Rs m152,993251,555 60.8%   
Gross profit Rs m25,66981,480 31.5%  
Depreciation Rs m8,87410,554 84.1%   
Interest Rs m1,406745 188.8%   
Profit before tax Rs m16,75173,990 22.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,48520,098 22.3%   
Profit after tax Rs m12,26653,892 22.8%  
Gross profit margin %16.932.9 51.5%  
Effective tax rate %26.827.2 98.6%   
Net profit margin %8.121.8 37.2%  
BALANCE SHEET DATA
Current assets Rs m139,864198,235 70.6%   
Current liabilities Rs m84,361106,652 79.1%   
Net working cap to sales %36.637.0 99.0%  
Current ratio x1.71.9 89.2%  
Inventory Days Days6919 360.5%  
Debtors Days Days10852 208.7%  
Net fixed assets Rs m94,439135,778 69.6%   
Share capital Rs m907586 154.9%   
"Free" reserves Rs m135,229218,713 61.8%   
Net worth Rs m136,136219,299 62.1%   
Long term debt Rs m1611,684 9.6%   
Total assets Rs m234,302334,013 70.1%  
Interest coverage x12.9100.3 12.9%   
Debt to equity ratio x00 15.4%  
Sales to assets ratio x0.60.7 87.2%   
Return on assets %5.816.4 35.7%  
Return on equity %9.024.6 36.7%  
Return on capital %13.333.8 39.4%  
Exports to sales %053.8 0.0%   
Imports to sales %016.4 0.0%   
Exports (fob) Rs mNA133,248 0.0%   
Imports (cif) Rs mNA40,615 0.0%   
Fx inflow Rs m51,027133,248 38.3%   
Fx outflow Rs m21,08144,946 46.9%   
Net fx Rs m29,94688,302 33.9%   
CASH FLOW
From Operations Rs m18,21833,289 54.7%  
From Investments Rs m-12,3965,987 -207.0%  
From Financial Activity Rs m-18,853-13,648 138.1%  
Net Cashflow Rs m-13,03125,831 -50.4%  

Share Holding

Indian Promoters % 46.6 48.8 95.5%  
Foreign collaborators % 0.3 3.1 9.1%  
Indian inst/Mut Fund % 40.3 38.4 105.2%  
FIIs % 19.0 23.7 80.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.1 48.2 110.3%  
Shareholders   299,620 243,315 123.1%  
Pledged promoter(s) holding % 0.0 22.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   PROCTER & GAMBLE HEALTH  COLINZ LABOR  ADESHWAR MEDITEX  HESTER BIOSCIENCES  CIPLA  



Today's Market

SGX Nifty Up 84 Points; Indicates Firm Opening for Indian Stock Markets(SGX Nifty)

The SGX Nifty opened on a positive note today. At 8:10 am, it was trading up by 84 points, or 0.5% higher at 17,695 levels.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (down 2.0% YoY). Sales on the other hand came in at Rs 57 bn (down 3.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of AUROBINDO PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Sansera Engineering IPO: Key Points to Consider(Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore(Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

The Top Stocks to Sell in this Bull Market(Profit Hunter)

Sep 8, 2021

When I saw the list of so-called 'value stocks' published by a leading brokerage, my worst fears came true.

5 Indian Companies that are Leading the AI Race(Views On News)

Sep 9, 2021

During the pandemic, India reported the highest increase in the use of AI at 45% compared to other major economies. AI has potential to add US$90 bn to the Indian economy by 2025.

Revenge Travel is Here. 9 Stocks Likely to Benefit(Views On News)

Sep 4, 2021

The term 'revenge travel' refers to the desire of going on a vacation after an extended period of lockdown.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Sep 17, 2021 09:42 AM

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS